GW&K Investment Management LLC Buys 4,371 Shares of Charles River Laboratories International, Inc. $CRL

GW&K Investment Management LLC lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,025 shares of the medical research company’s stock after acquiring an additional 4,371 shares during the period. GW&K Investment Management LLC owned approximately 0.21% of Charles River Laboratories International worth $20,152,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cerity Partners LLC increased its stake in Charles River Laboratories International by 35.1% in the 4th quarter. Cerity Partners LLC now owns 6,248 shares of the medical research company’s stock worth $1,246,000 after acquiring an additional 1,623 shares during the last quarter. LPL Financial LLC increased its stake in Charles River Laboratories International by 2.3% in the 4th quarter. LPL Financial LLC now owns 27,468 shares of the medical research company’s stock worth $5,479,000 after acquiring an additional 629 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Charles River Laboratories International by 321.7% during the fourth quarter. Franklin Resources Inc. now owns 120,883 shares of the medical research company’s stock worth $24,114,000 after purchasing an additional 92,217 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in shares of Charles River Laboratories International by 19.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 2,903 shares of the medical research company’s stock worth $579,000 after purchasing an additional 465 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in shares of Charles River Laboratories International by 23.0% during the fourth quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company’s stock worth $102,058,000 after purchasing an additional 95,619 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.0%

NYSE CRL opened at $186.10 on Thursday. The stock’s 50-day simple moving average is $172.94 and its two-hundred day simple moving average is $182.24. Charles River Laboratories International, Inc. has a twelve month low of $143.06 and a twelve month high of $228.88. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $8.96 billion, a price-to-earnings ratio of -49.50, a PEG ratio of 2.17 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter last year, the business posted $2.34 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts forecast that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

Analyst Ratings Changes

CRL has been the subject of several recent analyst reports. Robert W. Baird set a $213.00 price objective on Charles River Laboratories International in a report on Friday, May 8th. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their price objective for the stock from $167.00 to $219.00 in a report on Friday, May 29th. UBS Group boosted their price objective on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Barclays boosted their price objective on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.